Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
HDGFL2 Biologics Sequence Review Report 2026: Hepatoma-derived growth factor-related protein 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HDGFL2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
HDGFL1 Biologics Sequence Review Report 2026: Hepatoma-derived growth factor-like protein 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HDGFL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
HCAR2 Biologics Sequence Review Report 2026: Hydroxycarboxylic acid receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HCAR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
HCAR1 Biologics Sequence Review Report 2026: Hydroxycarboxylic acid receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HCAR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
HBEGF Biologics Sequence Review Report 2026: Proheparin-binding EGF-like growth factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HBEGF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GRK2 Biologics Sequence Review Report 2026: G protein-coupled receptor kinase 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GRK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GRIN1 Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, NMDA 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GRIN1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GNRHR2 Biologics Sequence Review Report 2026: Putative gonadotropin-releasing hormone II receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GNRHR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GLYR1 Biologics Sequence Review Report 2026: Cytokine-like nuclear factor N-PAC Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GLYR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GIG44 Biologics Sequence Review Report 2026: Putative insulin-like growth factor 2-associated protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GIG44 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GHSR Biologics Sequence Review Report 2026: Growth hormone secretagogue receptor type 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GHSR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
GAGE12J Biologics Sequence Review Report 2026: G antigen 12J Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GAGE12J sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
884
885
886
887
888
>>
2926
>